Ms Chow joined Novo Nordisk in February 2026 as executive vice president Product & Portfolio Strategy, which incorporates Commercial Strategy, Global Medical Affairs and Business Development across all therapy areas.

Ms Chow is not registered as an executive of Novo Nordisk A/S with the Danish Business Authority.

Ms Chow joined Novo Nordisk from Merck KGaA in Germany. As member of the Merck Healthcare Executive Committee Ms Chow held the role of executive vice president and head of China and International, overseeing the healthcare business outside of North America. She also served as global head of the Cardiovascular, Metabolism, and Endocrinology portfolio, which included therapies for diabetes, cardiovascular, thyroid, and growth disorders. In addition, Ms Chow was responsible for Global Health and Health Equity. Previously, Ms Chow has held leadership roles of increasing global, regional and country responsibility in the pharmaceutical industry, including leadership position at Roche, where she led the pharmaceutical business in China, and at Bayer Healthcare in versatile roles. Before joining the pharmaceutical industry in 1997 Ms Chow started her career as a business analyst for Deloitte Consulting in London.

Since 2017, Ms Chow has served as a Non-Executive Director on the Supervisory Board of Beiersdorf AG, Germany.

• 1996: Dual degree in European Business Administration - Diplom Kauffrau from Berlin School of Economics and Law, Germany and BA First Class Honors from Anglia Ruskin University, Cambridge, United Kingdom.

Ms Chow is Chinese-born German national, born July 1971.